Kinetics of Factor X activation by the membrane-bound complex
of Factor IXa and Factor VIIIa

Mikhail A. PANTELEEV*†, Evgenyi L. SAENKO‡, Natalya M. ANANYEVA† and Fazool I. ATAULLAKHANOV*‡§

*Laboratory of Physical Biochemistry of Blood, National Research Center for Hematology, Russian Academy of Medical Sciences, Novozavodskii pr. 4a, Moscow, 125167, Russia, †Jerome H. Holland Laboratory for the Biomedical Sciences, American Red Cross, 15601 Crabbs Branch Way, Rockville, MD 20855, U.S.A., ‡Laboratory of Metabolic Modelling and Bioinformatics, Institute of Theoretical and Experimental Biophysics, Prospect Nauky 4, Pushchino, Moscow Region, 192267, Russia, and §Faculty of Physics, Moscow State University, Leninskie Gory, Moscow, 119992, Russia

INTRODUCTION

fX (Factor X) activation during blood coagulation occurs via two pathways: the extrinsic tenase complex formed by Factor VIIa and tissue factor, and the intrinsic tenase complex composed of fIXa (Factor IXa) and fVIIia (Factor VIIIa) [1]. There is a consensus that physiological coagulation is initiated by extrinsic tenase, while its propagation is provided by positive feedback via intrinsic tenase [1–3]. The deficiencies of the components of intrinsic tenase, fVIIia and fIXa, lead to severe bleeding disorders, haemophilia A and B respectively [3,4], which emphasizes the importance of this complex.

fIXa is an M, 44 000 two-chain vitamin K-dependent serine protease capable of hydrolysing the Arg194–Ile195 peptide bond in the fX molecule, which leads to its activation [5]. Although this reaction can proceed slowly in solution, it is significantly accelerated in the presence of negatively charged phospholipid surfaces [6]. In vivo, these surfaces are mainly provided by activated platelets and plasma lipoproteins [7]. Erythrocytes have been reported to contribute substantially to providing pro-coagulant surface in blood [8], but this fact is not generally accepted [9,10]. For in vitro studies of fX activation by intrinsic tenase, synthetic phospholipid vesicles [usually composed of PS (phosphatidylserine) and PC (phosphatidylcholine) at a 25:75 molar ratio] are often used to substitute for physiological surfaces.

The rate of the reaction is increased further by the presence of fVIIia, a non-enzymic cofactor protein. After fIXa, fVIIia and fX bind to the platelet membrane or to the surface of phospholipid vesicle [12], fIXa forms a complex with fVIIia on the phospholipid surface (in solution, the complex is also formed, but with dramatically lower affinity [11]), which can activate fX five orders of magnitude more rapidly than fIXa in solution [6]. In turn, fXa forms a homologous complex with fVa, prothrombinase complex, which catalyses the conversion of prothrombin into thrombin [12].

During the last decade, a number of studies reported kinetic data on fX activation by intrinsic tenase in the presence of either phospholipid vesicles or platelets. The apparent kinetic constants of this reaction [6,11,13], the apparent equilibrium constants of fIXa and fVIIia dissociation [11,14–16], and the parameters of the binding of fIXa, fVIIia and fX to phospholipids [17,18] or platelets [19–22] have been determined. However, although a substantial amount of empirical information has been obtained, the mechanisms of the tenase complex assembly and function remain poorly understood. For prothrombinase, the first model was suggested two decades ago [23,24]. In contrast, the only theoretical study on intrinsic tenase [25] investigated the external regulation of the tenase depending on pathways of activation and inhibition of fIXa, fVIIia and fXa, but did not consider interactions between coagulation factors and phospholipid surfaces. Two simple models considering this interaction have been recently proposed as parts of larger models of the blood coagulation system [26,27]. However, these studies do not focus on intrinsic tenase specifically. In the present study, we attempted to combine

Intrinsic tenase consists of activated Factors IX (IXa) and VIII (VIIIa) assembled on a negatively charged phospholipid surface. In vivo, this surface is mainly provided by activated platelets. In vitro, phosphatidylcholine/phosphatidylserine vesicles are often used to mimic natural pro-coagulant membranes. In the present study, we developed a quantitative mathematical model of Factor X activation by intrinsic tenase. We considered two situations, when complex assembly occurs on either the membrane of phospholipid vesicles or the surface of activated platelets. On the basis of existing experimental evidence, the following mechanism for the complex assembly on activated platelets was suggested: (i) Factors IXa, VIIIa and X bind to their specific platelet receptors; (ii) bound factors form complexes on the membrane: platelet-bound Factor VIIIa provides a high-affinity site for Factor X and platelet-bound Factor IXa provides a high-affinity site for Factor VIIIa; (iii) the enzyme–cofactor–substrate complex is assembled. This mechanism allowed the explanation of co-operative effects in the binding of Factors IXa, VIIIa and X to platelets. The model was reduced to obtain a single equation for the Factor X activation rate as a function of concentrations of Factors IXa, VIIIa, X and phospholipids (or platelets). The equation had a Michaelis–Menten form, where apparent \( V_\text{max} \) and \( K_m \) were functions of the factors’ concentrations and the internal kinetic constants of the system. The equation obtained can be used in both experimental studies of intrinsic tenase and mathematical modelling of the coagulation cascade. The approach of the present study can be applied to research of other membrane-dependent enzymic reactions.

Key words: blood coagulation, Factor VIII, Factor IX, Factor X, mathematical modelling, platelet.
accumulated experimental data and existing theoretical concepts, and to develop a detailed mathematical model describing quantitatively the kinetics of $f\text{X}$ activation by the $f\text{IXa}–f\text{VIIa}$ complex on activated platelets or phospholipid vesicles. For activated platelets, we propose a reaction mechanism, according to which $f\text{X}$ and $f\text{VIIa}$ bind from plasma to their specific low-affinity high-capacity receptors on the platelet surface to be transferred to high-affinity receptors formed by $f\text{VIIa}$ and $f\text{IXa}$ respectively.

Portions of this work were presented at the XIX Congress of the International Society on Thrombosis and Haemostasis, 12–18 July 2003, Birmingham, U.K. [27a].

MATERIALS AND METHODS

Concepts of the model

The model is based on the mechanism depicted in Figure 2. $f\text{IXa}$, $f\text{VIIa}$ and $f\text{X}$ bind to the membrane and subsequently interact by means of diffusion. We disregarded the possibility of direct interaction between solution-phase proteins and surface-bound proteins on the basis of previous reports [23,28,29]. We did not consider the formation of the tenase complex in solution because of its high dissociation constant in the absence of either phospholipids or platelets [11]. $f\text{X}$ activation by $f\text{IXa}$ alone was also ignored, being slow in comparison with activation of $f\text{X}$ by the $f\text{IXa}–f\text{VIIa}$ complex [13].

Two approaches have been suggested to describe surface-mediated reactions. Nesheim et al. [23] proposed a concept of ‘interface shell’ between membrane and solution, where local concentrations of substrate and enzyme are high, and the local increase in concentration accounts for acceleration of the catalysis. The other approach considers two-dimensional reactions on the surface [28]. These approaches are mathematically equivalent, so we do not distinguish between them. It is necessary to point out that the approach used does not consider that at high concentrations of phospholipid vesicles, the bound proteins can segregate to different vesicles.

Area of applicability of Model 1

Model 1 describes the activation of $f\text{X}$ by the $f\text{IXa}–f\text{VIIa}$ complex assembled on the surface of synthetic PS/PC (phospholipid vesicles composed of PS and PC) at a molar ratio of 25:75. This model is designed to describe the reaction under the following conditions: human proteins, physiological conditions ($37{}^\circ\text{C}$, pH 7.2–7.4, 2 mM $\text{Ca}^{2+}$, 150 mM NaCl), $f\text{IXa}$ ($f\text{VIIa}$) concentration within picomolar to low nanomolar range, $f\text{X}$ concentration within high nanomolar to low micromolar range; phospholipid or high micromolar concentration.

Area of applicability of Model 2

Model 2 describes activation of $f\text{X}$ by the $f\text{IXa}–f\text{VIIa}$ complex assembled on the membrane of activated platelets. This model is designed to describe the reaction under the following conditions: human proteins and platelets, physiological conditions ($37{}^\circ\text{C}$, pH 7.2–7.4, 2 mM $\text{Ca}^{2+}$, 150 mM NaCl), $f\text{IXa}$ ($f\text{VIIa}$) concentration in picomolar to low nanomolar range, $f\text{X}$ concentration in high nanomolar to low micromolar range; platelet concentration is in picomolar to low nanomolar range, $f\text{X}$ and $f\text{Va}$ approx. 100–1000 nM; and PS/PC, approx. 1–1000 $\mu$M), we disregarded the fact that $f\text{IXa}$ and $f\text{VIIa}$ occupy binding sites on the phospholipid surface. We assumed that $f\text{X}$ is the only factor that can considerably occupy the membrane and displace other factors. Fifthly (for platelets only), platelets in the model have three types of specific binding sites, for $f\text{IXa}$, $f\text{VIIa}$ and $f\text{X}$ respectively (Table 2). The pre-coagulant activity of activated platelets depends on the type of activator [21,33]. In the present study, we considered only thrombin-activated platelets. Because the number of binding sites that appears after activation by thrombin does not depend on the thrombin concentration within a wide range [19], we assumed that the number of sites of each type is constant (Table 2) and did not consider competition between the factors for these sites [19–21]. This assumption is not valid for an in vivo situation, since $f\text{X}$ competes with prothrombin [20] for the binding sites, and $f\text{IXa}$ and $f\text{VIIa}$ share part of their sites with $f\text{IX}$ and $f\text{VIII}$ respectively [19,21]. Therefore, to adjust our model to plasma conditions, some corrections described in the Discussion should be introduced.

Fitting of generated curves

The binding curves obtained theoretically were fitted to the one-site (see Figure 5A–5C) or two-site (see Figure 5B, upper curve) standard binding model using the direct non-linear least-squares method implemented in Microlcal Origin 6.0 (Microlcal Software). The apparent parameters of Michaelis kinetics $V_{\max}$ and $K_{\text{m, s}}$, shown in Figures 2 and 3, were obtained with the same method.

RESULTS

The mechanism of assembly of the $f\text{IXa}–f\text{VIIa}–f\text{X}$ complex on PS/PC vesicles

An enzyme–cofactor–substrate ternary complex can be assembled via various pathways. If we assume that coagulation factors have to bind to the membrane before complex assembly (see the Materials and methods section), then the range of possible two-dimensional reactions leading to assembly of the $f\text{IXa}–f\text{VIIa}–f\text{X}$ complex is limited to those shown in Figure 1. All possible combinations of binary complexes would give seven unique models of a ternary complex assembly [34]. The data of multiple studies strongly suggest that at least one binary complex, composed of
Table 1 Parameters of the model describing intrinsic tenase on phospholipids (Model 1)

<table>
<thead>
<tr>
<th>Experimentally determined parameter</th>
<th>Experimental value</th>
<th>Experimental conditionsa</th>
<th>Reference</th>
<th>Relationship between model and experimental parameters</th>
<th>Value used in the model</th>
</tr>
</thead>
<tbody>
<tr>
<td>$k_{cat}$ (app)</td>
<td>1740 min$^{-1}$</td>
<td>$P = 25 , \mu M$ PS/PC</td>
<td>[13]</td>
<td>Eqn A46</td>
<td>$k_{cat}^{local} = 720 , \text{min}^{-1}$</td>
</tr>
<tr>
<td></td>
<td>136 min$^{-1}$</td>
<td>$P = 25 , \mu M$ PS/PC</td>
<td>[11]</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>198 nM min$^{-1}$</td>
<td>$P = 5 , \mu M$ PS/PC</td>
<td>[6]</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>436 nM min$^{-1}$</td>
<td>$P = 10 , \mu M$ PS/PC</td>
<td>[6]</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>436 nM min$^{-1}$</td>
<td>$P = 25 , \mu M$ PS/PC</td>
<td>[6]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>$K_0$ (app)</td>
<td>190 nM</td>
<td>$P = 25 , \mu M$ PS/PC</td>
<td>[13]</td>
<td>Eqn A39, eqn A47</td>
<td>$k_{VIIIa-X}^{local}/k = 9.2 \times 10^{-4}$</td>
</tr>
<tr>
<td></td>
<td>233 nM</td>
<td>$P = 25 , \mu M$ PS/PC</td>
<td>[11]</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>24 nM</td>
<td>$P = 5 , \mu M$ PS/PC</td>
<td>[6]</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>24 nM</td>
<td>$P = 10 , \mu M$ PS/PC</td>
<td>[6]</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>82 nM</td>
<td>$P = 25 , \mu M$ PS/PC</td>
<td>[6]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>$V_0$ (app)</td>
<td>1.4 nM</td>
<td>$P = 25 , \mu M$ PS/PC</td>
<td>[16]</td>
<td>Eqn A42</td>
<td>$k_{VIIIa-X}^{local}/k = 7 \times 10^{-6}$</td>
</tr>
<tr>
<td></td>
<td>2.3 nM</td>
<td>$P = 25 , \mu M$ PS/PC</td>
<td>[11]</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>0.07 nM</td>
<td>$P = 10 , \mu M$ PS/PC</td>
<td>[15]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>$K_i^{P}$</td>
<td>580 nM</td>
<td></td>
<td>[43]</td>
<td></td>
<td>40 nM</td>
</tr>
<tr>
<td></td>
<td>150 nM</td>
<td></td>
<td>[17]</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>49 nM</td>
<td></td>
<td>[44]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>$S_0$</td>
<td>$2 \times 42^{a,b}$</td>
<td></td>
<td>[17]</td>
<td></td>
<td>84</td>
</tr>
<tr>
<td>$S_0^{P}$</td>
<td>$2 \times 42^{a,b}$</td>
<td></td>
<td>[43]</td>
<td></td>
<td>930 nM</td>
</tr>
<tr>
<td>$S_0^{IXa}$</td>
<td>930 nM</td>
<td></td>
<td>[44]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>$S_0^{VIIIa}$</td>
<td>1000 nM</td>
<td></td>
<td>[45]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>$S_0^{VIIIa}$</td>
<td>$2 \times 42^{a,b}$</td>
<td></td>
<td>[17]</td>
<td></td>
<td>84</td>
</tr>
<tr>
<td>$K_{VIIIa}^{VIIIa}$</td>
<td>0.65 nM$^{-1}$</td>
<td></td>
<td>[18]</td>
<td></td>
<td>0.65 nM</td>
</tr>
<tr>
<td>$S_0^{IXa}$</td>
<td>89 nM</td>
<td></td>
<td>[46]</td>
<td></td>
<td>360</td>
</tr>
<tr>
<td></td>
<td>170 nM</td>
<td></td>
<td>[46]</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>262 nM</td>
<td></td>
<td>[47]</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

a Only the data necessary to obtain the model parameters from the corresponding experimentally determined parameters are presented in this column.

The value was obtained for bovine proteins.

The values used in the model are underlined.

We assume that $S_0^{IX} \approx S_0$ on the basis of [48].

For the PS/PC/phosphatidylethanolamine (47/60) vesicles, at pH 6.0.

For the PS/PC/phosphatidylethanolamine (30/75/2.5) vesicles.

For the PS/PC/phosphatidylethanolamine (20/75/2.5) vesicles.

For the PS/PC/phosphatidylethanolamine (25/75) vesicles.

For the PS/PC/phosphatidylethanolamine (20/75/25/2.5) vesicles.

For the PS/PC/phosphatidylethanolamine (20/75/25/2.5) vesicles.

For the PS/PC/phosphatidylethanolamine (25/75) vesicles.

b The values used in the model are underlined.

c The values used in the model are underlined.

Table 2 Parameters of the model describing intrinsic tenase on activated platelets (Model 2)

<table>
<thead>
<tr>
<th>Experimentally determined parameter</th>
<th>Experimental value</th>
<th>Experimental conditionsa</th>
<th>Reference</th>
<th>Relationship between model and experimental parameters</th>
<th>Value used in the model</th>
</tr>
</thead>
<tbody>
<tr>
<td>$V_{max}$</td>
<td>12.4 nM$^{-1}$</td>
<td>$[IXa] = 10 , \mu M, [VIIa] = 5 , \text{units} \cdot \text{ml}^{-1}$</td>
<td>[13]</td>
<td>Eqn A71</td>
<td>$k_{cat}^{local} = 6350 , \text{min}^{-1}$</td>
</tr>
<tr>
<td></td>
<td>12.4 nM$^{-1}$</td>
<td>$n = 5 \times 10^6 , \text{platelets} \cdot \text{ml}^{-1}$</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>2.5 nM$^{-1}$</td>
<td>$[IXa] = 1 , \text{mM}, [VIIa] = 5 , \text{units} \cdot \text{ml}^{-1}$</td>
<td>[41]</td>
<td>Eqn A77</td>
<td>$K_{VIIIa}/k = 1216 , \text{molecules/platelet}$</td>
</tr>
<tr>
<td></td>
<td>160 nM</td>
<td>$[IXa] = 10 , \mu M, [VIIa] = 5 , \text{units} \cdot \text{ml}^{-1}$</td>
<td>[13]</td>
<td>Eqn A71</td>
<td>$K_{VIIIa}/k = 1216 , \text{molecules/platelet}$</td>
</tr>
<tr>
<td></td>
<td>22.6$^a$ nM</td>
<td>$n = 5 \times 10^6 , \text{platelets} \cdot \text{ml}^{-1}$</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>$K_i^{IXa}$</td>
<td>0.56 nM</td>
<td>$\text{VIIa and IX were in saturation}$</td>
<td>[19]</td>
<td>Eqn A68</td>
<td>$k_{VIIIa-X}^{local}/k = 278 , \text{molecules/platelet}$</td>
</tr>
<tr>
<td>$K_i^{P}$</td>
<td>320 nM</td>
<td></td>
<td>[20]</td>
<td></td>
<td>$320 , \text{nM}$</td>
</tr>
<tr>
<td>$\theta_{IXa}$</td>
<td>16 000 sites/platelet</td>
<td></td>
<td>[20]</td>
<td></td>
<td>$16 000 , \text{sites/platelet}$</td>
</tr>
<tr>
<td>$\theta_{VIIIa}$</td>
<td>2.57 nM</td>
<td></td>
<td>[19]</td>
<td></td>
<td>$2.57 , \text{nM}$</td>
</tr>
<tr>
<td>$\theta_{VIIIa}$</td>
<td>250 sites/platelet</td>
<td></td>
<td>[19]</td>
<td></td>
<td>$250 , \text{sites/platelet}$</td>
</tr>
<tr>
<td>$\theta_{IXa}$</td>
<td>1.5 nM</td>
<td></td>
<td>[21]</td>
<td></td>
<td>$1.5 , \text{nM}$</td>
</tr>
<tr>
<td>$\theta_{VIIIa}$</td>
<td>1.7 nM</td>
<td></td>
<td>[19]</td>
<td></td>
<td>$1.7 , \text{nM}$</td>
</tr>
<tr>
<td>$\theta_{IXa}^{VIIIa}$</td>
<td>750 sites/platelet</td>
<td></td>
<td>[21]</td>
<td></td>
<td>$750 , \text{sites/platelet}$</td>
</tr>
<tr>
<td>$k_{cat}^{IXa-VIIIa}$</td>
<td>30 nM</td>
<td></td>
<td>[21]</td>
<td>Eqn A66</td>
<td>$k_{cat}^{IXa-VIIIa} = 1655 , \text{molecules/platelet}$</td>
</tr>
</tbody>
</table>

a Only the data necessary to obtain the model parameters from the corresponding experimentally determined parameters are presented in this column.

The values used in the model are underlined.

fXa and fVIIa actually exists [14,35]. This narrows the number of possible assembly models down to four: (i) fIXa–fVIIa is the only possible binary complex; (ii) both the fIXa–fVIIa and fVIIIa–fX complexes exist; (iii) both the fIXa–fVIIIa and fIXa–fX complexes exist; (iv) all three binary complexes shown in Figure 1 exist. The fIXa–fVIIIa interaction does not seem to be affected.
The ternary complex of fIXa, fVIIIa, and fX can be assembled on the membrane via several possible pathways. There can be three possible binary complexes: (1) the fIXa–fVIIIa complex, (2) the fIXa–fX complex and (3) the fVIIIa–fX complex. Depending on which complexes do exist, their combination gives seven possible alternative models of the final complex assembly [34]: a single binary complex (1, 2 or 3) is required for assembly of the ternary complex; two complexes contribute to the ternary complex formation (1 and 2, 1 and 3, or 2 and 3); contribution of all three complexes (1, 2 and 3) is significant.

by the addition of IX [14], which is inconsistent with model ‘a’ (see the Appendix, eqn A40). The existing evidence suggests that both the fIXa–fX [6,13,28] and the fVIIIa–fX [22] binary complexes can be formed during fX activation. However, we have chosen model ‘b’ on the basis of the following evidence: (i) The estimated value of the local dissociation constant $K_{\text{IXa--fX local}}$ for fIXa and fX is approx. 0.05 (see the Appendix). This value exceeds the estimated value of the dissociation constant of fIXa and fVIIIa by four orders of magnitude and also exceeds the value of the estimated local Michaelis constant by two orders of magnitude (Table 1). This suggests that formation of the fIXa–fX complex in the presence of fVIII would be unfavourable and unlikely to contribute significantly to fX activation. (ii) During assembly of the homologous prothrombinase complex, the cofactor–substrate fVa–fII (Factor II) binary complex formation is the preferred pathway of prothrombin activation both in the absence [34] and in the presence [36] of phospholipid membrane. (iii) Recent data suggest that formation of the fVIIIa–fX complex is important during fX activation by intrinsic tenase on the surface of activated platelets [22]. Finally, we tested the accuracy of mechanism ‘b’ a posteriori. The model was modified to include formation of the fIXa–fX complex (eqns A35–A36). Substitution of eqns A35–A36 for eqns A27–A28 ($K_{\text{IXa--fX local}} = 0.05$) did not change the rates of fXa formation (the difference was less than 0.1% under various conditions; results not shown).

### Kinetics of intrinsic tenase on phospholipid vesicles

The theoretical concepts of the model are depicted in Figure 2(A). An important feature of this system is the non-specificity of the binding sites on PS/PC membranes. This implies that a protein in excess can displace other proteins, thus decreasing the efficiency of the reaction (in particular, it can lead to inhibition of the reaction by excess substrate or excess enzyme [23]). The process of the model development is detailed in the Appendix. It gives eqn A34 (see Appendix) for the initial rate of the fXa production by
the apparent Michaelis constant $K_m$ (app) were: 1 nM fIXa, 0.06 nM fVIIIa and increasing concentrations of phospholipids. To test the hypothesis that $K_m$ is increased due to an excess of phospholipid surface, $K_m$ was also calculated with regard to the fIXa–fVIIIa complex: 1/C indicates assembly of the final fIXa–fVIIIa–fX complex (see eqn A45) shown in Figure 3(B).

Theoretical dependence (solid curve) is obtained using Model 1 (eqns A34, A24, A27, A28 and A29). The values of the constants are listed in Table 1. The conditions of the experiment were: 200 nM fX, 1 nM fIXa, 0.06 nM fVIIIa and increasing concentrations of phospholipids. Data (■) taken from [18]. The apparent maximal velocity $V_{max}$ (■) and the apparent Michaelis constant $K_m$ (■) of fX activation by intrinsic tenase on concentration of PS/PC (25:75) vesicles. The calculations were carried out using Model 1 (eqns A34, A24, A27, A28 and A29). The values of the constants are listed in Table 1. The conditions of the simulation were: 1 nM fIXa, 0.06 nM fVIIIa and increasing concentrations of phospholipids. To find $V_{max}$ and $K_m$, the rate of fXa production is calculated at 1, 5, 10, 20, 50 and 100 nM of fX. The dependence of activation rate on fX concentration is approximated with the non-linear least-squares method (see the Materials and methods section). The solid lines are drawn with the help of B-spline interpolation.

The presence of fIXa and fVIIIa also changed: from approx. 750 to approx. 1200 sites/platelet in the absence of fIX [21], and from approx. 750 to approx. 1000 sites/platelet in the presence of fIXa [22]. A recent study has shown that in the presence of excess prothrombin (which displaced fX from approx. 160000 shared sites) and fIX (which displaced fIXa from approx. 300 out of approx. 515 shared sites), fVIIIa and fIX both bound to approx. 1000 sites/platelet. Moreover, if approx. 300 sites shared by fIX and fIXa are blocked by excess fIX, the number of fVIIIa sites increases only by approx. 250 sites [22].

The presence of fIXa and fVIIIa in the absence of fIX induced the appearance of approx. 1200 and not approx. 1000 highly specific binding sites for fX. We used these data to develop a comprehensive model of interaction of the factors on the platelet membrane. We took into consideration that the number of binding sites for fVIIIa in the presence of fIXa and fX increases by approx. 450 sites/platelet, which is close to the total number of fIXa-binding sites (515) per platelet. Moreover, if approx. 300 sites shared by fIX and fIXa are blocked by excess fIX, the number of fVIIIa sites increases only by approx. 250 sites [22], which is close to the number of sites left for fIXa.

The mechanisms of assembly of intrinsic tenase on activated platelets are under intensive investigation at present [37]. The current paradigm for intrinsic tenase assembly on the membrane of activated platelets is the so-called ‘three-receptor model’ suggested by Walsh and colleagues [21,22,38]. According to this model, fIXa, fVIIIa and fX possess individual, highly specific, but interacting, receptors on the surface of activated platelets. These factors bind independently to their receptors from plasma and form complexes on the membrane by means of two-dimensional diffusion [28,29,39].

It was shown that in the presence of fVIIIa and fX, the $K_d$ for fIXa binding to platelets was decreased from 2.57 nM to 0.56 nM, while the number of binding sites for fIXa remained constant [19].  

The apparent Michaelis constant $K_m$ (app) respectively, as shown in Figure 3(B).
receptor, forming a 1:1 complex. Considerations similar to those for the PS/PC vesicles allow us to exclude other models of the fIXa–fVIIIa–fX complex assembly. The final scheme of intrinsic tenase assembly on the surface of activated platelets is shown in Figure 2(B).

Kinetics of intrinsic tenase on activated platelets

The process of model development is detailed in the Appendix. This process gives eqn A60 (see Appendix) for the rate of fX activation by intrinsic tenase assembled on platelets (Model 2), where [Xm], [VIIIaM] and [IXaM] are given by eqns A57, A58 and A59 respectively (see Appendix). To avoid complex notation, the symbols denoting the constants and the concentrations are the same in the ‘platelet’ and ‘phospholipid’ sections of this paper, although the values and the meaning of these constants are different (Tables 1 and 2). Definitions of these constants and concentrations are given in the Appendix. Additional eqns A61, A62 and A63 can be used to calculate the total concentrations of bound fX, fVIIIa, and fIXa respectively, and thus to obtain the apparent dissociation constants and the numbers of binding sites. The model predicts that at near-physiological conditions, the rate of fX activation depends linearly on platelet concentration (Figure 4), in agreement with the earlier study [33]. Importantly, the form of eqn A62 suggests that fVIIIa in the presence of fIXa and fX has in fact several families of binding sites: its own binding sites on activated platelets and those provided by fIXa. Therefore we also performed the fitting of the upper curve in Figure 5(B) by the two-site model (Figure 5B, dotted line). While visually this curve is nearly indistinguishable from the one-site approximation (enlarged in the inset), it yields a quite different result: it predicts the existence of two types of binding sites, of 750 sites with Kd = 1.5 nM and 197 sites with Kd = 0.32 nM, with the effectiveness of approximation (in terms of the sum of squares of deviations) of 1.20 × 10−30, while for the one-site model it is 21.46.

DISCUSSION

In the present study, we have developed a detailed mathematical model of fX activation by intrinsic tenase, which is one of the most important reactions of blood coagulation. We have considered two most frequently occurring situations: (i) the pro-coagulant surface is provided by phospholipid vesicles (the model consists of eqns A54, A57, A66 and A59); (ii) the pro-coagulant surface is provided by phospholipid vesicles (the model consists of eqns A54, A57, A66 and A59).
Figure 5 Specific binding of each component of the fX-activating complex to platelets depends on the presence of two other components (theoretical curves)

(A) The binding of fIXa (at indicated increasing concentrations) to activated platelets (2 × 10^6 per ml) in the presence (○) or in the absence (■) of 5 nM fVIIIa and 1500 nM fX. The solid line shows the approximation of the curve (○) with the one-site binding model. (B) The binding of fVIIIa (at the indicated increasing concentrations) to activated platelets (2 × 10^6 per ml) in the presence (○) or in the absence (■) of 45 nM fIXa and 1500 nM fX. The broken line represents the approximation of the curve (○) with the one-site binding model. The dotted line shows the approximation of the same curve with the two-site binding model. The inset shows the low-concentration section of the plot. (C) The binding of fX (at indicated increasing concentrations) to activated platelets (2 × 10^6 per ml) in the presence (○) or in the absence (■) of 10 nM fIXa and 10 nM fVIIIa. The solid line shows the approximation of the curve (○) with the two-site binding model. The calculations of the binding of fIXa, fVIIIa and fX were carried out using eqns A63, A62 and A61 respectively. The constants are listed in Table 2. The binding of fIXa to the shared fIXa/fIX sites is not considered in these calculations. The results of approximations are given in Table 3.

Table 3 Binding of coagulation factors to thrombin-activated platelets: theoretical results

<table>
<thead>
<tr>
<th>Ligand</th>
<th>Two other factors</th>
<th>Number of binding sites/platelet (n)</th>
<th>Kd (app) (nM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>fIXa</td>
<td>Absent</td>
<td>250</td>
<td>2.57</td>
</tr>
<tr>
<td></td>
<td>Present</td>
<td>250</td>
<td>0.69</td>
</tr>
<tr>
<td>fVIIIa</td>
<td>Absent</td>
<td>750</td>
<td>1.5</td>
</tr>
<tr>
<td></td>
<td>Present</td>
<td>926 (750 and 193)^2</td>
<td>1.1 (1.5 and 0.34)^2</td>
</tr>
<tr>
<td>fX</td>
<td>Absent</td>
<td>16 000</td>
<td>320</td>
</tr>
<tr>
<td></td>
<td>Present</td>
<td>16 002 and 755^2</td>
<td>320 and 28.7^2</td>
</tr>
</tbody>
</table>

a The conditions of calculations are given in the legend to Figure 5.
b Fixed values.
c Obtained values.
d Fitting to the two-site binding model.

provided by activated platelets (the model consists of eqns A60, A57, A58 and A59). The first experimental design is frequently used for in vitro experiments, as phospholipid vesicles represent a standard model of the pro-coagulant surface, while the second situation occurs in vivo. An advantage of this approach is that the final model is a simple equation which has the form:

\[
d[Xa]/dt = f([IXa], [VIIIa], [X], [PC/PS] or [platelets])
\]  

(1)

in contrast with the models of prothrombinase suggested earlier [23,24]. This makes our model a handy tool for experimental design and analysis, although imposing some limitations on the area of applicability. Our approach can also be used to model the kinetics of other membrane-dependent reactions in the coagulation cascade and other biochemical networks, such as activation of prothrombin by prothrombinase, activation of protein C by the complex of thrombin and thrombomodulin, inactivation of fVa by activated protein C, reactions of complement, etc.

FX activation by intrinsic tenase assembled on phospholipid vesicles

The model of intrinsic tenase assembled on phospholipids (Model 1) is in agreement with the experimental data on the rate of fX activation at different phospholipid concentrations (Figure 3A). It predicts a linear dependence of the apparent Michaelis constant and the Kd (app) of fIXa and fVIIIa on phospholipid concentration (Figure 3B and eqn A42); the V_max value has a maximum, which is also in agreement with the reported experimental data [6,35]. Although the model of intrinsic tenase on synthetic phospholipids describes an artificial system, this model may have applications in vivo. Indeed, as shown, the pro-coagulant surface for tenase assembly can be provided by plasma lipoproteins [7], the surface of which is most likely to be non-specific. If so, eqns A34, A24, A27, A28 and A29, although developed for synthetic PS/PC vesicles, could be used for lipoproteins upon substitution of the values of kinetic constants.

Activation of fX by intrinsic tenase assembled on activated platelets

The existence of highly specific receptors for fIXa, fVIIIa and fX on activated platelets and correlation between the rate of fX activation and the occupancy of these receptors is well established [28,39]. These receptors seem to be complex structures consisting of phospholipids and membrane proteins [21]. The apparent affinity and the apparent number of binding sites for each component of the fX-activating complex (fIXa, fVIIIa and fX) depend in a complex way on the concentration of two other components (for details, see the Results section). Based on these data, we suggest a kinetic scheme of fIXa, fVIIIa and fX interactions with platelets (Figure 2B). Our model is based on the ‘three-receptor model’ proposed by Walsh and colleagues [21,22] and it states...
that: (i) each of the proteins (fIXa, fVIIIa or fX) independently binds to its specific receptor and subsequently they form complexes on the membrane by means of two-dimensional diffusion [28]; (ii) membrane-bound fX is ‘passed on’ to the specific site consisting of fVIIIa bound to its receptor, and fX–fVIIIa complex subsequently binds fIXa (the hypothesis proposed in [22]); however, the ‘classic’ order of complex assembly (fIXa and fVIIIa form the enzymic complex and then bind fX) is also possible; (iii) by analogy with ‘b’, the enzyme–cofactor complex and the final enzyme–cofactor–substrate complex are formed on the site consisting of fIXa bound to its receptor (the hypothesis of the present study). With this assembly mechanism, fX would bind from solution to a large area containing approx. 10 000 low-affinity receptors, and be subsequently transferred to approx. 1000 high-affinity sites provided by fVIIIa [38]; where, again, they would be directed to approx. 250 sites of fIXa, where catalysis occurs.

Our calculations using Model 2 show that the scheme in Figure 2(B) gives results that are consistent with experimentally observed effects (see Figure 5 and Table 3). The model also predicts that the presence of both fIXa and fX leads to the appearance of a new family of high-affinity (approx. 0.3 nM) binding sites for fVIIIa; however, precise experiments are required to test this prediction (Figure 5B and Table 3). Thorough examination of fVIIIa (at low concentrations) binding to activated platelets may provide evidence for or against our model. A more direct approach to detect these newly formed fIXa-dependent fVIIIa-binding sites is to block fVIIIa’s own sites. For example, this can be done by an excess of the isolated C2 domain of fVIIIa, which contains the phospholipid-binding site of fVIII. It was shown that the C2 domain competes with fVIIIa for its binding sites on platelets, but does not interact with fIXa [42]. Experimental determination of dependences of the apparent $V_{max}$ and $K_m$ on platelet concentration and their comparison with model predictions (Figure 4B) can also significantly contribute to the understanding of the processes of complex formation on the phospholipid membrane. Further investigation of this mechanism requires experimental determination of dependence of $K^{VIII\alpha}$, $n^{VIII\alpha}$ on [fIXa] and [X], and $K^{IX\alpha}$, $n^{IX\alpha}$ on [fVIIIa] and [X]. Comparison of these dependences with the predictions of different models seems to be a promising approach of investigation of this mechanism.

Possible applications and extensions of the model

In their present forms, Models 1 and 2 can describe only the initial kinetics of fX activation and only in the systems that contain no additional proteins except for fIXa, fVIIIa and fX. It is important, however, to have a model which is valid for the conditions of plasma and for various protein environments. In this section, we summarize the approaches that can considerably extend the area of applicability of the model.

APPENDIX

Derivation of basic equations

Initially, we derive general equations to describe the binding of a protein from solution to a membrane and association/dissociation of two membrane-bound proteins. First, we consider the binding of some factor F to a membrane. The binding equation is:

$$[F^b] \cdot K^F = ([F] - [F^b]) \cdot (N^F - [F^b])$$  \hspace{1cm} (A1)

where $[F^b]$ is the concentration of bound factor F with respect to total volume, [F] is the total factor F concentration, $K^F$ is the equilibrium dissociation constant of factor F and its binding site on the membrane, $N^F$ is the concentration of factor F binding sites on the membrane.

Product inhibition on PS/PC

First, eqns A34, A24, A27, A28 and A29 of Model 1, describing intrinsic tenaee on phospholipids, were derived based on the assumption that fX is the only protein to occupy the membrane of vesicles. This assumption is applicable only for analysis of the initial kinetics of the reaction. At later stages, accumulation of fIXa may produce the effect of product inhibition: fIXa will bind to the membrane and displace fIXa, fVIIIa and fX. The binding of fIXa to phospholipids occurs with the same affinity and stoichiometry as the binding of fIX [17], and this product competition can be described by Model 1 after substitution of eqn 2 for eqn A23:

$$[X^b] = \frac{[X] \cdot P/S^x}{K^x + [X] + [Xa] + P/S^x}$$  \hspace{1cm} (2)

Intrinsic tenaee assembly on activated platelets in plasma

Although activated platelets express highly specific binding sites, a few plasma proteins homologous with fIXa, fVIIIa or fX can compete to a certain extent for the respective binding sites. The most important is prothrombin, which shares with fX the binding sites on activated platelets [20]. When systems containing prothrombin are considered, eqn A57 should be modified according to the standard competition formula:

$$[X^b] = \frac{[X] \cdot N \cdot n^x}{K^x + \left(1 + \frac{[X]}{K^x} + \frac{[II]}{K^II}\right)}$$  \hspace{1cm} (3)

where $K^II$ is the equilibrium dissociation constant for prothrombin binding to activated platelets. The validity of eqn 3 is supported by its agreement (results not shown) with the experiments of intrinsic tenaee competitive inhibition by prothrombin fragment 1 [28]. fVIIIa and fIXa share part of their specific binding sites with their predecessors fVIII and fIX respectively [19,21]. However, plasma fVIII is quantitatively bound to von Willebrand factor, which effectively inhibits fVIII binding to platelets [21]. Therefore correction of the model for possible competition between fVIIIa and fVIII for platelets in plasma is not required. In contrast with fVIII, fIX has been shown not only to affect, but also even to potentiate fX activation by intrinsic tenaee, though the mechanism of this effect remains unclear [40]. Further elucidation of this mechanism is required in order to develop an adequate model of fX activation on activated platelets in the presence of fIX.

We are grateful to Dr Mikhail V. Ovanesov (National Research Center for Hematology) for careful review and constructive criticism of the manuscript. This study was supported in part by grant from Russian Foundation for Basic Research, project No. 03-04-4838, to F.I.A., and by NATO Collaborative Linkage Grant No. 979210 to E.L.S. and F.I.A.
with respect to total volume. From this quadratic equation, the equilibrium concentration of bound factor F is:

$$[F^*] = \frac{(K_F^d + [F] + N^F) - \sqrt{(K_F^d + [F] + N^F)^2 - 4 \cdot [F] \cdot N^F}}{2} \tag{A2}$$

Assuming that

$$\sqrt{[F] \cdot N^F} \ll K_F^d + [F] + N^F \tag{A3}$$

we can use the first-order approximation of the square root in eqn A2 to obtain:

$$[F^*] \approx \frac{(K_F^d + [F] + N^F) - \left( (K_F^d + [F] + N^F) - \frac{1}{2} \cdot \frac{4 \cdot [F] \cdot N^F}{K_F^d + [F] + N^F} \right)}{2} = \frac{[F] \cdot N^F}{K_F^d + [F] + N^F} \tag{A4}$$

Eqn A4, being simpler and more convenient for analysis than eqn A2, has a wider area of applicability than the standard binding model:

$$[F^*] = \frac{[F] \cdot N^F}{K_F^d + [F]} \tag{A5}$$

Eqn A3 holds for fIXa, fVIIIa, fX and platelet/phospholipid membrane in the area of applicability specified for our model (see the Materials and methods section). To describe the interaction between membrane-bound factors, we introduce the local concentration of factor F, $[F^*]_{\text{local}}$. Physically, this local concentration is either the two-dimensional surface density of factor F on the surface of a platelet/vesicle [23,24,28] or the three-dimensional concentration of factor F in the thin ‘interface shell’ between the bulk solution and the platelet/vesicle [23,24]. These two approaches are mathematically equivalent, so we do not specify the dimensionality of $[F^*]_{\text{local}}$: it is a platelet/vesicle [28] or the three-dimensional concentration of factor F, $[F^*]_{\text{local}}$. Physically, this local concentration is either the two-dimensional surface density of factor F on the surface of a platelet/vesicle [23,24] or the three-dimensional concentration of factor F in the thin ‘interface shell’ between the bulk solution and the platelet/vesicle [23,24]. These two approaches are mathematically equivalent, so we do not specify the dimensionality of $[F^*]_{\text{local}}$: it can be either nmol/cm$^2$ or nmol/l. By its definition, $[F^*]_{\text{local}}$ is directly proportional to $[F^*]$ and is inversely proportional to the concentration of platelets/vesicles [23,24,28]:

$$[F^*]_{\text{local}} = \frac{k}{N} \cdot [F^*] \tag{A6}$$

where $N$ is the concentration of platelets or phospholipids, and $k$ is the proportionality factor. The dimensionality of $k$ depends on the dimensionality of $[F^*]_{\text{local}}$. If $N$ were expressed in phospholipid vesicles per litre, then parameter $k$ would have simple physical interpretation: its dimensionality will be [litre$^{-1}$] and the value of $k$ will be reciprocal relative to the volume of the ‘interface shell’ of a single vesicle. Next, we consider interaction of two membrane-bound proteins, factors F1 and F2. Let their local equilibrium dissociation constant equal $K_1^{1-2}_{\text{local}}$. Dimensionality of this local constant is identical with that of $[F^*]_{\text{local}}$, and the constant has a straightforward definition as the ratio of product of equilibrium local concentrations of complex-free factors to the concentration of the complex. Then the local concentration of the F1–F2, complex by analogy with eqns A2, A3, and A4 is defined:

$$[F_1^B \cdot F_2^B]_{\text{local}} = \frac{[F_1^B]_{\text{local}} \cdot [F_2^B]_{\text{local}}}{K_1^{1-2}_{\text{local}} \cdot [F_1^B]_{\text{local}} + [F_2^B]_{\text{local}}} \tag{A7}$$

Rearranging eqn A7 with the help of eqn A6, we obtain the concentration of the complex with respect to the total volume:

$$[F_1^B \cdot F_2^B] = \frac{[F_1^B] \cdot [F_2^B]}{K_1^{1-2}_{\text{local}} \cdot N/k + [F_1^B] + [F_2^B]} \tag{A8}$$

By analogy with eqn A4, eqn A8 is valid as long as either $[F_1^B]$ or $[F_2^B]$ is much smaller than the other value or as long as both are much smaller than $K_1^{1-2}_{\text{local}}$. The approach used to derive eqns A4 and A8 is frequently used throughout the following computations.

**Kinetics of intrinsic tenase on phospholipids**

Through $[\text{IX}^a]$, $[\text{VIII}^a]$, and $[\text{X}^a]$, we denote the concentrations of fIXa, fVIIIa and fX respectively, which are bound to membrane, but are free (i.e. are not in a complex). The concentration with superscript ‘B’ denotes the total concentrations of a bound factor (i.e. $[\text{IX}^B] = [\text{IX}^a] + [\text{IX}^a - \text{VIIIa}^a] + [\text{IX}^a - \text{VIIIa}^a - \text{X}^a]$). To obtain quasi-steady concentrations of membrane complexes, we use eqns A9, A10 and A11 for the reactions on the membrane in Figure 2(A):

$$\frac{d[\text{IX}^B - \text{VIIIa}^B]}{dt} = k_1 \cdot [\text{IX}^a] \cdot [\text{VIII}^a] - k_{-1} \cdot [\text{IX}^B - \text{VIIIa}^B] - k_2 \cdot [\text{IX}^B - \text{VIIIa}^B] \cdot [\text{X}^a] + k_{-2} \cdot [\text{IX}^B - \text{VIIIa}^B - \text{X}^a]$$

$$+ k_{\text{cat}}^\text{local} \cdot [\text{IX}^B - \text{VIIIa}^B - \text{X}^B] = 0 \tag{A9}$$
where we denote:

\[
\begin{align*}
\frac{d[VIIIa^b \cdot X^b]}{dt} &= k_3 \cdot [VIIIa^m] \cdot [X^b] - k_{-3} \cdot [VIIIa^b \cdot X^b] - k_4 \cdot [IXa^m] \cdot [VIIIa^b \cdot X^b] + k_{-4} \cdot [IXa^b \cdot VIIIa^b \cdot X^b] = 0 \\
\frac{d[IXa^b \cdot VIIIa^b \cdot X^b]}{dt} &= k_2 \cdot [IXa^b \cdot VIIIa^b] \cdot [X^b] - k_{-2} \cdot [IXa^b \cdot VIIIa^b \cdot X^b] + k_4 \cdot [IXa^b] \cdot [VIIIa^b \cdot X^b] - k_{-4} \cdot [IXa^b \cdot VIIIa^b \cdot X^b] \\
&- k_{\text{local}} \cdot [IXa^b \cdot VIIIa^b \cdot X^b] = 0
\end{align*}
\]  

(A10)
\[d[IXa^b \cdot VIIIa^b \cdot X^b]\]

(A11)

where \(k_1, k_2, k_3, k_4\) are effective kinetic association constants of the direct reactions 1, 2, 3 and 4 of Figure 2(A); \(k_{-1}, k_{-2}, k_{-3}, k_{-4}\) are the rate constants of the respective reverse reactions. According to eqn A8, \(k_1, k_2, k_3, k_4\) are inversely proportional to phospholipid concentration \(P\) (see eqns A18, A19 and A20). Solving this system of algebraic equations, we obtain \([IXa^b \cdot VIIIa^b], [VIIIa^b \cdot X^b]\) and \([IXa^b \cdot VIIIa^b \cdot X^b]\):  

\[
[IXa^b \cdot VIIIa^b] = \frac{k_3 \cdot [IXa^m] \cdot [VIIIa^m] + k_{-3} \cdot [IXa^b \cdot VIIIa^b \cdot X^b] + k_{\text{local}} \cdot [IXa^b \cdot VIIIa^b \cdot X^b]}{k_{-1} + k_2 \cdot [X^b]}  
\]  

(A12)

\[
[VIIIa^b \cdot X^b] = \frac{k_3 \cdot [VIIIa^b] \cdot [X^b] + k_{-3} \cdot [IXa^b \cdot VIIIa^b \cdot X^b]}{k_{-2} + k_4 \cdot [IXa^b]}  
\]  

(A13)

\[
[IXa^b \cdot VIIIa^b \cdot X^b] = \frac{k_2 \cdot [IXa^b \cdot VIIIa^b] \cdot [X^b] + k_4 \cdot [IXa^b] \cdot [VIIIa^b \cdot X^b]}{k_{-2} + k_{-4} + k_{\text{local}}}  
\]  

(A14)

The set of eqns A12–A14 is solved after the reduction of high-order terms in eqns A12 and A13 (see [34] for the analysis of a similar system):  

\[
[IXa^b \cdot VIIIa^b] \approx \frac{[IXa^m] \cdot [VIIIa^m]}{P \cdot K_{\text{IXa-VIIIa local}} / k}  
\]  

(A15)

\[
[VIIIa^b \cdot X^b] \approx \frac{[VIIIa^b] \cdot [X^b]}{P \cdot K_{\text{VIIIa-X local}} / k}  
\]  

(A16)

\[
[IXa^b \cdot VIIIa^b \cdot X^b] \approx \frac{[IXa^m] \cdot [VIIIa^m] \cdot [X^b]}{P \cdot K_{\text{IXa-VIIIa local}} / k \cdot P \cdot K_{\text{local}} / k} = \frac{[IXa^b \cdot VIIIa^b] \cdot [X^b]}{P \cdot K_{\text{local}} / k}  
\]  

(A17)

where we denote:

\[
P \cdot K_{\text{IXa-VIIIa local}} / k = \frac{k_{-1} \cdot k_1}{k_2}  
\]  

(A18)

\[
P \cdot K_{\text{VIIIa-X local}} / k = \frac{k_{-3} \cdot k_3}{k_4}  
\]  

(A19)

\[
P \cdot K_{\text{local}} / k = \frac{k_{-2} + k_{-4} + k_{\text{local}}}{k_2 \cdot k_4 \cdot K_{\text{IXa-VIIIa local}} / K_{\text{VIIIa-X local}}}  
\]  

(A20)

The next step is to find connection between the bulk ([IXa], [VIIIa] and [X]) and bound ([IXa^m], [VIIIa^b] and [X^m]) factor concentrations. Binding sites for factors on phospholipid vesicles are non-specific. Therefore, to calculate the concentrations of bound factors, competition between factors has to be taken into account. Moreover, the binding of different factors to phospholipids occurs with different stoichiometry. We assume that the only factor to occupy the membrane significantly is fX (see the Materials and methods section). The equations of equilibrium binding are:

\[
K_{\text{IXa}} \cdot [IXa^m] \cdot S^{IXa} = ([IXa] - [IXa^m] - [IXa^b \cdot VIIIa^m] - [IXa^b \cdot VIIIa^b \cdot X^b]) \cdot (P - [X^m]) \cdot S^{X}  
\]  

(A21)

\[
K_{\text{VIIIa}} \cdot [VIIIa^m] \cdot S^{VIIIa} = ([VIIIa] - [VIIIa^m] - [VIIIa^b \cdot X^b] - [IXa^b \cdot VIIIa^b] - [IXa^b \cdot VIIIa^b \cdot X^b]) \cdot (P - [X^m]) \cdot S^{X}  
\]  

(A22)

\[
K_{\text{X}} \cdot [X^m] \cdot S^{X} = ([X] - [X^m] - [VIIIa^b \cdot X^b] - [IXa^b \cdot VIIIa^b \cdot X^b]) \cdot (P - [X^m]) \cdot S^{X}  
\]  

(A23)

where \(S^{IXa}, S^{VIIIa}\) and \(S^{X}\) are the doubled stoichiometries of binding of fIX, fVIIIa and fX respectively to phospholipid. The values are doubled because only a part of phospholipid molecules (from half to two thirds, depending on the vesicle size) is located on the outer leaflet of the membrane of the vesicle [17]. Accordingly, the expressions \(P/S^{IXa}, P/S^{VIIIa}\) and \(P/S^{X}\) give the concentrations of binding sites for the factors with respect to total volume. Solution of eqns A21, A22 and A23 is:

\[
[X^m] = \frac{[X] \cdot P/S^{X}}{K_{\text{X}} + [X] + P/S^{X}}  
\]  

(A24)

© 2004 Biochemical Society
\[
[VIIIa^M] = \frac{[VIIIa]}{1 + \frac{K_{d}^{VIIIa} \cdot S_{VIIIa}}{P - [X^M] \cdot S^X} + \frac{[X^M]}{P \cdot K_{d}^{VIIIa-X \ local} / k} + \left( 1 + \frac{[X^M]}{P \cdot K_{m}^{local} / k} \right) \cdot \frac{[IXa^M]}{P \cdot K_{d}^{IXa-VIIIa \ local} / k}}
\]  
(A25)

\[
[IXa^M] = \frac{[IXa]}{1 + \frac{K_{d}^{IXa} \cdot S_{IXa}}{P - [X^M] \cdot S^X} + \left( 1 + \frac{[X^M]}{P \cdot K_{m}^{local} / k} \right) \cdot \frac{[VIIIa^M]}{P \cdot K_{d}^{IXa-VIIIa \ local} / k}}
\]  
(A26)

To solve this system, we take into consideration that we do not need individual solutions for \([VIIIa^M]\) and \([IXa^M]\), but only for their product. For better readability of equations, we denote:

\[
A = 1 + \frac{K_{d}^{VIIIa} \cdot S_{VIIIa}}{P - [X^M] \cdot S^X} + \frac{[X^M]}{P \cdot K_{d}^{VIIIa-X \ local} / k}
\]  
(A27)

\[
B = 1 + \frac{K_{d}^{IXa} \cdot S_{IXa}}{P - [X^M] \cdot S^X}
\]  
(A28)

\[
C = 1 + \frac{[X^M]}{P \cdot K_{m}^{local} / k}
\]  
(A29)

After rearrangement, eqns A25 and A26 can be written in the form:

\[
[VIIIa^M] = \frac{[VIIIa] - C \cdot [IXa^M] \cdot [IXa^M]}{A}
\]  
(A30)

\[
[IXa^M] = \frac{[IXa] - C \cdot [IXa^M] \cdot [VIIIa^M]}{B}
\]  
(A31)

Multiplication of these equations and reduction of the fourth-order term \(([IXa^M] \cdot [VIIIa^M])^2\) gives the following solution:

\[
[IXa^B-VIIIa^B] = \frac{[IXa] \cdot [VIIIa]}{P \cdot K_{d}^{IXa-VIIIa \ local} / k \cdot A \cdot B + C \cdot ([VIIIa] + [IXa])}
\]  
(A32)

\[
[IXa^B-VIIIa^B] = \frac{[IXa] \cdot [VIIIa]}{P \cdot K_{d}^{IXa-VIIIa \ local} / k \cdot A \cdot B + C \cdot ([VIIIa] + [IXa])}
\]  
(A33)

The rate of fX activation is defined by the equation obtained from eqns A17 and A33:

\[
\frac{d[Xa]}{dt} = \frac{k_{local} \cdot [IXa] \cdot [VIIIa]}{P \cdot K_{d}^{IXa-VIIIa \ local} / k \cdot A \cdot B + C \cdot ([VIIIa] + [IXa]) \cdot [X^M] / P \cdot K_{m}^{local} / k}
\]  
(A34)

If we consider the most general model ‘d’ of the fIXa–fVIIIa–fX complex assembly (all the binary complexes shown in Figure 1 exist), then these parameters will have the form:

\[
A = 1 + \frac{K_{d}^{VIIIa} \cdot S_{VIIIa}}{P - [X^M] \cdot S^X} + \frac{[X^M]}{P \cdot K_{d}^{VIIIa-X \ local} / k}
\]  
(A35)

\[
B = 1 + \frac{K_{d}^{IXa} \cdot S_{IXa}}{P - [X^M] \cdot S^X} + \frac{[X^M]}{P \cdot K_{d}^{IXa-X \ local} / k}
\]  
(A36)

The value of \(K_{d}^{IXa-X \ local} / k\) can be estimated from the value of the apparent Michaelis constant for the fX activation by fIXa. Specifically, \(K_{d}^{IXa-X \ local} / k\) is obtained from the ratio of the Michaelis constant and phospholipid concentration (in a manner similar to eqn A47). Estimation on the basis of [13] gives a value of \(K_{d}^{IXa-X \ local} / k = 0.05\).

It is difficult to measure the values of local two-dimensional constants \(k_{local} \cdot K_{m}^{local} / k \), \(K_{d}^{VIIIa-X \ local} / k\) and \(K_{d}^{IXa-VIIIa \ local} / k\) in direct experiments. However, they can be obtained from measurable parameters of the reaction of fX activation (Table 1). From eqn A27, the \(K_d\) (app) of the fIXa–fVIIIa complex is defined as:

\[
K_d\ (\text{app}) = \frac{A \cdot B}{C}
\]  
(A37)
By substituting eqns A27, A28 and A29 into eqn A37, rearranging and simplifying (assuming for this experiment that \([X^M] \ll P/S^X\)), we get:

\[
K_d (\text{app}) \approx \frac{P \cdot K_{IXa-VIIIa local}/k}{1 + \frac{[X^M]}{P \cdot K_{local}/k}}
\]

(A38)

This equation provides information about two constants. First, this constant is reported not to be influenced by fX addition [14]. Therefore

\[
K_{VIIIa-X local}/k = K_{local}/k
\]

(A39)

Otherwise, the \(K_d (\text{app})\) would depend upon fX addition:

\[
K_d (\text{app}) \approx \frac{P \cdot K_{IXa-VIIIa local}/k}{1 + \frac{[XM]}{P \cdot K_{local}/k}}
\]

(A40)

From eqns A38 and A39 it follows that:

\[
K_d (\text{app}) \approx \frac{P \cdot K_{IXa-VIIIa local}/k}{P}
\]

(A41)

(A42)

Under the conditions used in Table 1 of [11] and in [13], fVIIIa is in excess, and from eqn A34 we obtain:

\[
\frac{d[Xa]}{dt} = \frac{k_{local}/k \cdot [IXa] \cdot [X^M]}{P \cdot K_{local}/k + [X^M]} = \frac{k_{local}/k \cdot K_d \cdot S^X + P}{1 + K_{local}/k \cdot S^X + P} \frac{[IXa] \cdot [X]}{1 + K_{local}/k \cdot S^X + P}
\]

(A43)

The apparent catalytic and Michaelis constants are expressed:

\[
k_{\text{cat}} (\text{app}) = \frac{k_{local}/k \cdot K_d \cdot S^X + P}{1 + K_{local}/k \cdot S^X}
\]

(A44)

\[
K_m (\text{app}) = \frac{K_m/k \cdot K_d \cdot S^X + P}{1 + K_{local}/k \cdot S^X}
\]

(A45)

Finally, the values of model parameters are:

\[
k_{\text{cat}} = k_{\text{cat}} (\text{app}) \cdot (1 + K_{local}/k \cdot S^X)
\]

(A46)

\[
K_{local}/k = \frac{K_m (\text{app})}{(K_d - K_m (\text{app})) \cdot S^X + P} \approx \frac{K_m (\text{app})}{P}
\]

(A47)

Summarizing, the rate of fX activation by intrinsic tenase on phospholipids is determined by eqn A34, into which eqns A24, A27, A28 and A29 are substituted. These equations form Model 1. The parameters, used in these equations, can be obtained from the experimentally determined values with the help of eqns A39, A42, A46 and A47 (Table 1).

**Kinetics of intrinsic tenase on activated platelets**

The process of intrinsic tenase assembly on the surface of platelet membrane differs from that on the surface of phospholipid vesicles. Coagulation factors bind to their specific sites, and there is no competition for the surface between factors. However, bound factors and their specific receptors interact in a complex way, which complicates the modelling. To avoid complex notation, the symbols denoting the constants and the concentrations are the same both in the ‘platelet’ and ‘phospholipid’ sections of the present paper, although these constants have different values and different meanings (Tables 1 and 2). As for phospholipids, \([IXa^M]\), \([VIIIa^M]\) and \([X^M]\) are the concentrations of fIXa, fVIIIa and fX respectively, which are bound to the membrane, but are free there. To obtain the quasi-steady concentrations of complexes, we use the equations of reactions written in accordance with Figure 2(B), which are identical with eqns A9, A10 and A11. The association constants used in these equations, however, are the apparent constants, which are inversely proportional to the concentration of surface, according to eqn A8. This fact is used below in eqns A51, A52 and A53. Solving
this system of algebraic equations, we obtain the values of $[\text{IXa}^\text{B} - \text{VIIIa}^\text{B}]$, $[\text{VIIIa}^\text{B} - \text{X}^\text{B}]$ and $[\text{IXa}^\text{B} - \text{VIIIa}^\text{B} - \text{X}^\text{B}]$, which are given by eqns A12, A13 and A14. By analogy with phospholipids:

$$[\text{IXa}^\text{B} - \text{VIIIa}^\text{B}] \approx \frac{[\text{IXa}^\text{M}] \cdot [\text{VIIIa}^\text{M}]}{N \cdot K_d^{\text{IXa-VIIIa local}} / k}$$  \hspace{1cm} (A48)

$$[\text{VIIIa}^\text{B} - \text{X}^\text{B}] \approx \frac{[\text{VIIIa}^\text{M}] \cdot [\text{X}^\text{M}]}{N \cdot K_d^{\text{VIIIa-X local}} / k}$$  \hspace{1cm} (A49)

$$[\text{IXa}^\text{B} - \text{VIIIa}^\text{B} - \text{X}^\text{B}] \approx \frac{[\text{IXa}^\text{M}] \cdot [\text{VIIIa}^\text{M}] \cdot [\text{X}^\text{M}]}{N \cdot K_d^{\text{IXa-VIIIa local}} / k \cdot N \cdot K_m^{\text{local}} / k}$$  \hspace{1cm} (A50)

where

$$N \cdot K_d^{\text{IXa-VIIIa local}} / k = \frac{k_{-1}}{k_1}$$  \hspace{1cm} (A51)

$$N \cdot K_d^{\text{VIIIa-X local}} / k = \frac{k_{-3}}{k_3}$$  \hspace{1cm} (A52)

$$N \cdot K_m^{\text{local}} / k = \frac{k_{-2} + k_{-4} + k_{\text{cat}}}{k_2 + k_4 - K_d^{\text{IXa-VIIIa local}} / k_d^{\text{VIIIa-X local}}}$$  \hspace{1cm} (A53)

The next step is to find a connection between the bulk ([IXa], [VIIIa] and [X]) and the local ([IXa]^M, [VIIIa]^M and [X]^M) concentrations. Note that eqn A55 suggests that the fVIIIa–fX complex can dissociate from the platelet membrane with the same rate as fVIIIa [22]. We did not consider this reaction in the model for phospholipids, assuming that $[\text{VIIIa}^\text{M}] \gg [\text{VIIIa}^\text{B} - \text{X}^\text{B}]$. To simplify the system, we do not consider the reverse reaction (binding of fX to platelet-bound fVIIIa from solution) because its contribution is negligible under normal conditions [22,28]. However, this simplification makes it impossible to use our model to describe experiments in which fX sites are blocked with prothrombin [22]. The binding equations are:

$$K_d^{\text{IXa}} \cdot [\text{IXa}^\text{M}] = ([\text{IXa}] - [\text{IXa}] - [\text{IXa}^\text{B} - \text{VIIIa}^\text{B}] - [\text{IXa}^\text{B} - \text{VIIIa}^\text{B} - \text{X}^\text{B}] \cdot (N \cdot n^{\text{IXa}} - [\text{IXa}^\text{M}] - [\text{IXa}^\text{B} - \text{VIIIa}^\text{B}]) - [\text{IXa}^\text{B} - \text{VIIIa}^\text{B}])$$  \hspace{1cm} (A54)

$$K_d^{\text{VIIIa}} \cdot ([\text{VIIIa}^\text{M}] + [\text{VIIIa}^\text{B} - \text{X}^\text{B}]) = ([\text{VIIIa}] - [\text{VIIIa}] - [\text{IXa}^\text{B} - \text{VIIIa}^\text{B}] - [\text{IXa}^\text{B} - \text{VIIIa}^\text{B} - \text{X}^\text{B}] - [\text{VIIIa}^\text{B} - \text{X}^\text{B}]) \cdot (N \cdot n^{\text{VIIIa}} - [\text{VIIIa}^\text{M}] - [\text{VIIIa}^\text{B} - \text{X}^\text{B}])$$  \hspace{1cm} (A55)

$$K_d^{\text{X}} \cdot [\text{X}^\text{M}] = ([\text{X}] - [\text{X}] - [\text{VIIIa}^\text{B} - \text{X}^\text{B}] - [\text{IXa}^\text{B} - \text{VIIIa}^\text{B} - \text{X}^\text{B}]) \cdot (N \cdot n^{\text{X}} - [\text{X}^\text{M}])$$  \hspace{1cm} (A56)

Solution with the help of eqns A48, A49 and A50 gives:

$$[\text{X}^\text{M}] = \frac{[\text{X}] \cdot N \cdot n^{\text{X}}}{K_d^{\text{X}} + [\text{X}]}$$  \hspace{1cm} (A57)

$$[\text{VIIIa}^\text{M}] = \frac{[\text{VIIIa}] \cdot N \cdot n^{\text{VIIIa}}}{(K_d^{\text{VIIIa}} + [\text{VIIIa}]) \cdot \left(1 + \frac{[\text{X}^\text{M}]}{N \cdot K_d^{\text{VIIIa-X local}} / k}\right)}$$  \hspace{1cm} (A58)

$$[\text{IXa}^\text{M}] = \frac{[\text{IXa}] \cdot N \cdot n^{\text{IXa}}}{K_d^{\text{IXa}} + [\text{IXa}] \cdot \left(1 + \frac{[\text{VIIIa}^\text{M}]}{N \cdot K_d^{\text{IXa-VIIIa local}} / k} + \frac{[\text{VIIIa}^\text{M}] \cdot [\text{X}^\text{M}]}{N \cdot K_d^{\text{IXa-VIIIa local}} / k \cdot N \cdot K_m^{\text{local}} / k}\right)}$$  \hspace{1cm} (A59)

To obtain eqns A57–A59, we take into account that $[\text{IXa}] \gg [\text{IXa}^\text{M}] + [\text{IXa}^\text{B} - \text{VIIIa}^\text{B}] + [\text{IXa}^\text{B} - \text{VIIIa}^\text{B} - \text{X}^\text{B}]$, $[\text{VIIIa}] \gg [\text{VIIIa}^\text{M}] + [\text{VIIIa}^\text{B} - \text{X}^\text{B}] + [\text{IXa}^\text{B} - \text{VIIIa}^\text{B}] + [\text{IXa}^\text{B} - \text{VIIIa}^\text{B} - \text{X}^\text{B}]$, $[\text{X}] \gg [\text{X}^\text{M}] + [\text{VIIIa}^\text{B} - \text{X}^\text{B}] + [\text{IXa}^\text{B} - \text{VIIIa}^\text{B} - \text{X}^\text{B}]$ (see the Materials and methods section). In particular, with these additional assumptions, identical eqns A23 and A56 give eqns A24 and A57 respectively, which have different forms. The formula for the rate of fX activation has the form:

$$\frac{d[\text{IXa}]}{dt} = k_{\text{cat}} \cdot [\text{IXa}^\text{B} - \text{VIIIa}^\text{B} - \text{X}^\text{B}] = k_{\text{cat}} \cdot \frac{[\text{IXa}^\text{M}] \cdot [\text{VIIIa}^\text{M}] \cdot [\text{X}^\text{M}]}{N \cdot K_d^{\text{IXa-VIIIa local}} / k \cdot N \cdot K_m^{\text{local}} / k}$$  \hspace{1cm} (A60)

In summary, the rate of fX activation by intrinsic tenase on activated platelets is defined by eqn A60, into which eqns A57, A58 and A59 are substituted. These equations form Model 2. Besides, eqns A57, A58 and A59 allow total concentrations of bound factors
to be obtained:

\[
[X^a] = [X^M] + [\text{VIIIa}^B - X^B] + [\text{IXa}^B - \text{VIIHa}^B - X^B] = [X^M] \cdot \left(1 + \frac{[\text{VIIHa}^M]}{N \cdot K_d^\text{VIIa-X local}/k} + \frac{[\text{IXa}^M]}{N \cdot K_d^\text{IXa-VIIa local}/k \cdot N \cdot K_m^\text{IXa}/k}\right) \tag{A61}
\]

\[
[VIIIa^B] = [\text{VIIHa}^M] \cdot \left(1 + \frac{[X^M]}{N \cdot K_d^\text{VIIa-X local}/k} + \frac{[\text{IXa}^M]}{N \cdot K_d^\text{IXa-VIIa local}/k \cdot N \cdot K_m^\text{IXa}/k} + \frac{[\text{IXa}^M]}{N \cdot K_d^\text{IXa-VIIa local}/k \cdot N \cdot K_m^\text{IXa}/k}\right) \tag{A62}
\]

\[
[\text{IXa}^B] = \frac{[\text{IXa}] \cdot N \cdot n_{\text{IXa}}}{K_d^{\text{IXa}}} \left(1 + \frac{[\text{VIIIa}^M]}{N \cdot K_d^{\text{IXa-VIIa local}}/k} + \frac{[\text{IXa}^M]}{N \cdot K_d^\text{IXa-VIIa local}/k \cdot N \cdot K_m^\text{IXa}/k}\right) + [\text{IXa}] \tag{A63}
\]

It follows from these equations that, for example for fIXa, the number of binding sites at saturating concentrations of fVIIIa and fX does not change (see eqn A63), while the \( K_d \) (app) is decreased. As for phospholipids, we should obtain the values of local constants from the experimentally determined parameters (Table 2). The values of \( K_d^{\text{IXa-VIIa local}}/k \) and \( K_d^{\text{VIIa-X local}}/k \) can be obtained from the experiments of co-ordinate binding of factors to platelets. fVIIIa is known to form the binding site for fX with a \( K_d \) (app) of approx. 30 nM [21]. From eqns A49, A57 and A58, we see that in this case:

\[
[VIIIa^B - X^B] = \frac{[\text{VIIIa}^M] \cdot N \cdot n_{\text{VIIIa}} \cdot n_X^{\text{local}}}{K_d^{\text{VIIIa-X local}}/k + n_X^{\text{local}}} + [X] \cdot (K_d^{\text{VIIIa}} + [\text{VIIIa}] \cdot \left(\frac{K_d^{\text{VIIIa-X local}}/k}{K_d^{\text{VIIIa-X local}}/k + n_X^{\text{local}}} + [X]\right)) \tag{A64}
\]

and we obtain:

\[
K_d^{\text{VIIIa-X (app)}} = \frac{K_d^{\text{VIIIa-X}}}{K_d^{\text{VIIIa-X local}}/k + n_X^{\text{local}}} \tag{A65}
\]

\[
K_d^{\text{VIIIa local}}/k = \frac{K_d^{\text{VIIIa-X (app)}} \cdot n_X^{\text{local}}}{K_d^{\text{VIIIa}} - K_d^{\text{VIIIa-X (app)}}} \tag{A66}
\]

To obtain the local dissociation constant of fIXa and fVIIIa, \( K_d^{\text{local}}/k \), we use eqn A63. In the presence of excess fVIIIa and fX, the \( K_d \) (app) is:

\[
K_d^{\text{IXa (app)}} = \frac{K_d^{\text{IXa}}}{1 + \frac{n_{\text{IXa}}}{K_d^{\text{IXa-VIIIa local}}/k} \cdot \frac{1 + \frac{n_X^{\text{local}}}{K_d^{\text{IXa-X local}}/k}}{1 + \frac{n_X^{\text{local}}}{K_d^{\text{VIIIa-X local}}/k}}} \tag{A67}
\]

and the value of the local constant is:

\[
K_d^{\text{IXa-VIIIa local}}/k = \frac{K_d^{\text{IXa (app)}}}{K_d^{\text{IXa}} - K_d^{\text{IXa (app)}}} \cdot n_{\text{VIIIa}} \cdot \frac{1 + \frac{n_X^{\text{local}}}{K_d^{\text{IXa-VIIIa local}}/k}}{1 + \frac{n_X^{\text{local}}}{K_d^{\text{VIIIa-X local}}/k}} \tag{A68}
\]

Finally, to obtain the values of the local catalytic constant and the local Michaelis constants, we used two different experimental reports [13,41]. Under the conditions of the earlier study [13], when \( [\text{IXa}] = 10 \text{pM} \ll K_d^{\text{IXa}} \), we get from eqn A60:

\[
\frac{d[Xa]}{dt} = \frac{k_{\text{cat}}^{\text{local}} \cdot N \cdot n_{\text{IXa}} \cdot n_{\text{VIIIa}} \cdot n_X^{\text{local}} \cdot [\text{IXa}]}{K_d^{\text{IXa}} \cdot K_d^{\text{IXa-VIIIa local}}/k \cdot K_m^{\text{local}}/k \cdot \left(1 + \frac{n_X^{\text{local}}}{K_d^{\text{IXa-VIIIa local}}/k}\right)} \cdot [X] \tag{A69}
\]

\[
V_{\text{max}} = \frac{k_{\text{cat}}^{\text{local}} \cdot N \cdot n_{\text{IXa}} \cdot n_{\text{VIIIa}} \cdot n_X^{\text{local}} \cdot [\text{IXa}]}{K_d^{\text{IXa}} \cdot K_d^{\text{IXa-VIIIa local}}/k \cdot K_m^{\text{local}}/k \cdot \left(1 + \frac{n_X^{\text{local}}}{K_d^{\text{IXa-VIIIa local}}/k}\right)} \tag{A70}
\]

\[
k_{\text{cat}}^{\text{local}} = \frac{V_{\text{max}} \cdot K_d^{\text{IXa}} \cdot K_d^{\text{IXa-VIIIa local}}/k \cdot \left(1 + \frac{n_X^{\text{local}}}{K_d^{\text{IXa-VIIIa local}}/k}\right)}{N \cdot n_{\text{IXa}} \cdot n_{\text{VIIIa}} \cdot n_X^{\text{local}} \cdot [\text{IXa}]} \tag{A71}
\]
In contrast with [13], in [41], the factors saturate their binding sites, and from eqn A60 we get:

\[
\frac{d[X_a]}{dt} = \frac{k_{\text{cat}}^{\text{local}} \cdot n^{VIII_a} \cdot [X] \cdot N \cdot n^X}{K_{\text{m}}^{\text{local}} / k + n^{VIII_a}} \]

(A72)

\[
\frac{d[X_a]}{dt} = \frac{k_{\text{cat}}^{\text{local}}}{K_{\text{m}}^{\text{local}} / k + n^{VIII_a}} \cdot \frac{K_X^{\text{local}} \cdot n^{VIII_a} \cdot [X] \cdot N \cdot n^X}{1 + K_X^{\text{local}} / k + n^{VIII_a}} \]

(A73)

\[
K_n^{(\text{app})} \approx \frac{K_X^{\text{local}}}{n^X \cdot K_m^{\text{local}} / k + n^{VIII_a}} - \frac{n^{X_a} \cdot N \cdot n^X}{K_m^{\text{local}} / k + n^{VIII_a}}
\]

(A74)

\[
V_{\text{max}} = \frac{k_{\text{cat}}^{\text{local}}}{K_m^{\text{local}} / k + n^{VIII_a}} \cdot \frac{1 + K_m^{\text{local}} / k + n^{VIII_a}}{n^{VIII_a} / n^X} \cdot \frac{N}{n^X}
\]

(A75)

Values of local constants are:

\[
K_m^{\text{local}} / k \approx \frac{n^X \cdot K_n^{\text{local}} \cdot (\text{app})}{K_X^{\text{local}} - K_n^{\text{local}} \cdot (\text{app})}
\]

(A76)

\[
k_{\text{cat}}^{\text{local}} = \frac{V_{\text{max}} \cdot (1 + K_m^{\text{local}} / k + n^{VIII_a})}{n^{VIII_a} / n^X} \cdot \frac{N}{n^X}
\]

(A77)

REFERENCES

38 Willebrand factor and activated platelets and the effect of the FVIII B-domain on platelet binding. Biochemistry 36, 10760–10767

Received 17 November 2003/25 March 2004; accepted 22 April 2004
Published as BJ Immediate Publication 22 April 2004, DOI 10.1042/BJ20031748